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Abstract
Background: Blood pressure is considered to be a leading example of a valid surrogate endpoint. The aims of this
study were to (i) formally evaluate systolic and diastolic blood pressure reduction as a surrogate endpoint for
stroke prevention and (ii) determine what blood pressure reduction would predict a stroke benefit.
Methods: We identified randomised trials of at least six months duration comparing any pharmacologic anti-
hypertensive treatment to placebo or no treatment, and reporting baseline blood pressure, on-trial blood pressure,
and fatal and non-fatal stroke. Trials with fewer than five strokes in at least one arm were excluded. Errors-in-
variables weighted least squares regression modelled the reduction in stroke as a function of systolic blood
pressure reduction and diastolic blood pressure reduction respectively. The lower 95% prediction band was used to
determine the minimum systolic blood pressure and diastolic blood pressure difference, the surrogate threshold
effect (STE), below which there would be no predicted stroke benefit. The STE was used to generate the surrogate
threshold effect proportion (STEP), a surrogacy metric, which with the R-squared trial-level association was used to
evaluate blood pressure as a surrogate endpoint for stroke using the Biomarker-Surrogacy Evaluation Schema
(BSES3).
Results: In 18 qualifying trials representing all pharmacologic drug classes of antihypertensives, assuming a
reliability coefficient of 0.9, the surrogate threshold effect for a stroke benefit was 7.1 mmHg for systolic blood
pressure and 2.4 mmHg for diastolic blood pressure. The trial-level association was 0.41 and 0.64 and the STEP was
66% and 78% for systolic and diastolic blood pressure respectively. The STE and STEP were more robust to
measurement error in the independent variable than R-squared trial-level associations. Using the BSES3, assuming a
reliability coefficient of 0.9, systolic blood pressure was a B + grade and diastolic blood pressure was an A grade
surrogate endpoint for stroke prevention. In comparison, using the same stroke data sets, no STEs could be
estimated for cardiovascular (CV) mortality or all-cause mortality reduction, although the STE for CV mortality
approached 25 mmHg for systolic blood pressure.
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any medium, provided the original work is properly cited.Conclusions: In this report we provide the first surrogate threshold effect (STE) values for systolic and diastolic
blood pressure. We suggest the STEs have face and content validity, evidenced by the inclusivity of trial
populations, subject populations and pharmacologic intervention populations in their calculation. We propose that
the STE and STEP metrics offer another method of evaluating the evidence supporting surrogate endpoints. We
demonstrate how surrogacy evaluations are strengthened if formally evaluated within specific-context evaluation
frameworks using the Biomarker- Surrogate Evaluation Schema (BSES3), and we discuss the implications of our
evaluation of blood pressure on other biomarkers and patient-reported instruments in relation to surrogacy metrics
and trial design.
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Background
Substantive discussions of surrogate endpoint validation
began in the late 1980s and early 1990s partly driven by
the need to find valid biomarkers for Acquired Immu-
nodeficiency Syndrome (AIDS) randomised controlled
trials. A systematic review of the literature of statistical
methods, conceptual frameworks and schema [1],
recently incorporated as Appendix A in the Institute of
Medicine’s publication Evaluation of Biomarkers and
Surrogate Endpoints in Chronic Disease [2], found that
statistical validity was a key component of surrogate
endpoint evaluation. In this systematic review [1], the
1992 framework by Boissel et al [3], is considered to be
the first application of a rigorous multilayered schema
for surrogate endpoint evaluation. Boissel’s schema pro-
poses that evidence from pathophysiology (biological
plausibility), epidemiological studies and randomised
controlled trials is needed. Several other frameworks of
surrogate validity have been proposed [1,2], including
our approach which builds on Boissel’s framework. Our
schema, designed as an overall and comparative hier-
archical multidimensional framework for evaluating bio-
markers as surrogates, is the Biomarker-Surrogacy
Evaluation Schema (BSES). The BSES1 (also referred to
as Quantitative Surrogate Validation Levels of Evidence
Schema-QSVLES) published in 2007 [4], had three
domains, study design, target outcome and statistical
evaluation, as well as add-on penalties which captured
concepts of generalisability and risk-benefit. In 2008, the
BSES2 populated the statistical domain with specific sta-
tistical measures and criteria [1]. In 2010, the BSES3 [5]
replaced the penalties with a domain that specifically
evaluated clinical and pharmacologic generalisability of
the surrogate under evaluation, simplified the number of
ranks within each domain, and dropped criteria specific
to public health risk-benefit. The BSES3, is a matrix of
four domains each with four ranks (see Figure 1 and
Additional file 1: Scenarios illustrating the application of
the Biomarker-Surrogate (BioSurrogate) Evaluation
Schema (BSES3)). It provides a rank for each domain as
well as a combined score of surrogacy status. Using the
BSES3, the best performing surrogate requires excellent
statistical evidence from multiple randomised controlled
trials, irreversible morbidity, organ failure or death as
the target outcome, and evidence across different drug
class mechanisms and clinical risk populations. The
BSES3 is data and context driven; therefore, the surro-
gacy status of a biomarker may change over time as new
data and or contexts become available. The statistical
domain of the BSES is also informed by and updated to
incorporate innovations in statistical methodology.
The excellent rank statistical evidence specified in the
BSES requires high trial-level association of treatment
effects, high individual-level associations and high surro-
gate threshold effect proportion (STEP) between the
surrogate endpoint and the true clinical endpoint. Using
mixed model methods, Buyse, Molenberghs [6] and
their colleagues [7] proposed and have extensively devel-
oped the statistical methodology for trial-level and indi-
vidual-level associations between surrogate and true
clinical endpoints. These associations are coefficients of
determination of the trial-level effects of treatment on
both endpoints (R
2
trial) and of the patient-level associa-
tion between both endpoints (R
2
individual). These statis-
tics provide qualitative and different evaluations of the
surrogate endpoint. They are reported as a relative mea-
sure and can take any value from 0 to 1. The surrogate
threshold effect proportion (STEP), proposed by Lassere
[1], is also a relative measure, and is derived from its
absolute measure, the surrogate threshold effect (STE).
The STE, developed from work undertaken by Daniel
and Hughes [8], and independently proposed by Burzy-
kowski and Buyse [9] and Johnson et al [10,11], provides
a method of reporting surrogacy status in the units of
the surrogate, for example mmHg of blood pressure.
The STE uses a statistical model of past trials that mea-
sures both the surrogate and true clinical endpoints to
predict the outcome benefit as a function of the surro-
gate in a new trial that only measures the surrogate end-
point. As the STE is measured in the units of the
surrogate, the STE could be used to inform surrogate
validity for drug registration and drug reimbursement
decisions. The strongest relationships between surrogate
and outcome using the STE have been in oncology
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Page 2 of 21[10,7]. Here, surrogates such as progression-free survival
are being used to predict survival, yet the surrogate
itself, a composite of progression and survival, contains
the outcome, so some degree of prediction is expected.
By contrast, in the case of laboratory biomarker
surrogates, there is no such expected relationship. Of
laboratory biomarkers, as far as we could determine,
only an STE for CD4 cell count as a surrogate for pro-
gression to AIDS or death [8] (although not called an
STE in this early report) and LDL-cholesterol as a
Study Design Domain Study Design Domain
0  Biological plausibility & lower quality clinical studies e.g. cross-sectional observational studies 
1   Rank 0 and at least 2 good quality prospective observational cohort studies measuring S and T#
2  Rank 1 and at least 2 high quality adequately powered RCTs measuring S and T
3  Rank 1 and all, and at least 5 high quality adequately powered, RCTs measuring S and T
Target Outcome Domain Target Outcome Domain
0  Target is reversible disease-centred biomarker of harm
1  Target is irreversible disease-centred biomarker of harm
2  Target is patient-centred endpoint of reversible organ morbidity or clinical burden of disease or clinical harm
3  Target is patient-centred endpoint of irreversible organ morbidity or clinical burden of disease or severe 
irreversible clinical harm or death
Statistical Evaluation of  Statistical Evaluation of BioSurrogate BioSurrogate – – Target (B Target (B- -T) Domain T) Domain
0  Poor: Does not meet the criteria for Rank 1 
1  Fair: RCT R2
trial  0.2 AND STEP*   0.1  AND R2
ind  0.2 OR cohort data  R2
ind  0.4
2  Good: RCT R2
trial  0.4 AND STEP  0.2  AND R2
ind  0.4 
3  Excellent: RCT R2
trial  0.6 AND STEP  0.3 AND R2
ind is  0.6 (without data subdivision)**
BIOMARKER BIOMARKER- -SURROGATE (BIOSURROGATE) EVALUATION SCHEMA  SURROGATE (BIOSURROGATE) EVALUATION SCHEMA 
(BSES) (BSES)
BIOMARKER BIOMARKER- -SURROGATE DOMAINS SURROGATE DOMAINS
Generalisability Generalisability of  of BioSurrogate BioSurrogate- -Target Domain:  Target Domain: 
Clinical evidence across different risk populations & pharmacolo Clinical evidence across different risk populations & pharmacologic evidence across  gic evidence across 
different drug different drug- -class mechanisms class mechanisms
0  No clinical or pharmacologic evidence 
1  Clinical OR pharmacologic evidence 
2  Clinical AND pharmacologic evidence 
3  Consistent Clinical RCT AND pharmacologic RCT evidence
#   Where S is the surrogate / biomarker/ biosurrogate and T is the target / true outcome
*   STEP is defined as that proportion of the total range of the surrogate that is equal or larger than the STE
** Some analyses with few trials subdivide into centres to increase the number of data points
A high rank on any one or more domain should not be allowed to prevail over a low rank on one or 
more domain when determining the overall level of evidence because at least good evidence of 
surrogacy across all domains is needed for surrogate validity. An A, B+, B, B- level surrogate 
endpoint ranks at least 2 on all domains.
Steps to determine the level of evidence:
1. The one and the same ‘evidence-base’ is applied across all four domains when determining the level 
of evidence.
2. Sum the highest rankings achieved across the four domains. 
3. If any one domain is less than Rank 2, the level of evidence drops by one alphabetic category 
irrespective of the initial level. For example, B becomes a C, B- becomes a C- , C- becomes a D-
and so forth.
LEVEL OF EVIDENCE OF SURROGATE ENDPOINT MULTIDIMENSIONAL VALIDITY
12         level A
11- 9     level B+, B, B-
8 - 6     level C+, C, C-, D+, D, D-
5 - 3     level D+, D, D-, E+, E, E-
2 - 0     level E+, E, E- F+, F, F-
Figure 1 Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES2011).
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Page 3 of 21surrogate for cardiovascular mortality have been pub-
lished [11]. The STE and the STEP provide different
qualitative and quantitative statistical information with
respect to one another and with respect to trial-level
and individual-level measures of association, and we
suggest that evidence of surrogacy across several statisti-
cal methods is needed to comprehensively inform surro-
gate decision-making.
Regulators have approved drugs based on surrogate
endpoints [12,13]. Blood pressure is a leading example
[14]. Blood pressure is a physiological biomarker. The
acceptance of blood pressure as a valid surrogate end-
point is supported by evidence from large cohort studies
which found that high blood pressure was a risk factor
for vascular events [15], and from randomised con-
trolled trials which showed that reduction in blood pres-
sure reduced these events. Additional evidence for the
support of blood pressure as a valid surrogate endpoint
comes from recent meta-analyses of randomised con-
trolled trials and from meta-regressions [16,18]. The lit-
erature on biomarkers and surrogate endpoints consider
blood pressure the closest we have to a ‘gold standard’
surrogate endpoint. If so, the comparative performance
of blood pressure on any surrogate evaluation frame-
work is of importance. That the stroke reduction found
in randomised controlled trials of hypertension was
close to that predicted from epidemiological studies of
hypertension [3] was supportive evidence of blood pres-
sure as a valid surrogate for stroke. Yet, there has been
no quantitative evaluation of the surrogacy status of
blood pressure on any framework and no report has
determined a surrogate threshold effect (STE) for blood
pressure. These were the two aims of our study in the
context of systolic and diastolic blood pressure (BP) as
surrogate endpoints of stroke prevention.
Methods
Trial inclusion and exclusion criteria
Randomised trial evidence of the relationship of blood
pressure reduction and rate of stroke was reviewed from
the published literature. Trial inclusion criteria were
negatively (placebo or open-label) controlled trials that
randomised patients that (i) were at least six months
duration of pharmacologic treatment for primary or sec-
ondary prevention, (ii) used any anti-hypertensive regi-
men, (iii) reported baseline and on-trial blood pressure
for treated and for control patients, and (iv) reported
number of events for fatal and non-fatal stroke for trea-
ted and for control patients. A negatively controlled trial
was a trial with no mandatory anti-hypertensive treat-
ment requirement for patients in the control arm. How-
ever, discretionary treatment, for example, rescue
medication, was permitted. Exclusion criteria were (i)
trials that only recruited patients with chronic heart
failure, diabetes or chronic renal failure, (ii) trials in
patients with acute stroke or acute myocardial infarct,
(iii) trials designed to assess blood pressure in respon-
ders rather than all randomised patients, (iv) trials using
a second on-trial randomisation that re-assigned some
active arm patients to placebo treatment, (v) trials that
simultaneously evaluated multiple interventions target-
ing vascular risk (e.g. hypertension and hyperlipidaemia)
and (vi) trials with fewer than five cerebrovascular
(CVA) events per treatment arm [18]. We did not
require elevated blood pressure at entry as an inclusion
criterion.
Search strategy
Our first search strategy was a search of Medline (1950
to February 2009) for randomised trials of blood pres-
sure using exp Hypertension/(174,452) OR exp Blood
Pressure/(210,864) OR (blood pressure or hyperten* or
systolic or diastolic).mp. (523,114) that identified
528,263 citations. These were limited to (humans AND
clinical trial, all OR clinical trial, phase I OR clinical
trial, phase II OR clinical trial, phase III OR clinical trial
or controlled clinical trial OR multicentre study OR ran-
domized controlled trial) yielding 50,780 unique cita-
tions, a random selection of which identified most as
unsuitable for our objective and a systematic evaluation
of all was not feasible. Therefore, an alternative strategy
to identify trials that met our inclusion criteria was
applied.
Our second strategy was a rapid review process to
identify original trial reports that met our trial inclusion
criteria by sourcing secondary data identified in meta-
analyses of randomised trials of hypertension. We
searched Medline (1950 to May 2009) using the search
terms (exp Hypertension/(181,231) OR exp Blood Pres-
sure/(216,603) OR (blood pressure or hyperten* or sys-
tolic or diastolic).mp. (538,084); limited to humans AND
adults AND to meta-analysis OR reviews OR systematic
reviews. This yielded 1199 citations. A search of the
Cochrane Database identified 8 reviews that already had
been identified in the Medline search. The abstracts of
these 1199 citations were evaluated and 38 meta-ana-
lyses or systematic reviews reported trials that satisfied
our inclusion criteria (see Additional file 2 reference
list). The remaining meta-analyses did not contribute
trials because they were meta-analyses of trials that (i)
were of insufficient duration, (ii) did not address adult
patients with hypertension, (iii) were derivative analyses
of earlier meta-analyses with no new trials, or they were
not meta-analyses at all. All randomised controlled trial
reports identified from these 38 meta-analyses were
obtained to determine whether they met our inclusion/
exclusion criteria. One author (KJ) further hand-
searched all citations of the randomised controlled trial
Lassere et al. BMC Medical Research Methodology 2012, 12:27
http://www.biomedcentral.com/1471-2288/12/27
Page 4 of 21reports to identify trials that may have been missed by
the 38 meta-analyses.
Data extraction
Two authors (KJ, MS) independently extracted the data
from trial reports and uncertainty was further adjudi-
cated (ML). Intention-to-treat extractions were applied
throughout. We extracted the following for treated and
control patients: treatments at trial entry; initial, on-trial
and final diastolic and systolic blood pressure; fatal and
non-fatal stroke events (CVAs), and any other interven-
tions used. We also extracted all cardiovascular fatal
events and all-cause fatal events if the trial reported
fatal and non-fatal stroke events. Trials enrolling both
primary and secondary prevention patients were coded
as combined primary and secondary prevention. We
also extracted, if reported, information on trial: demo-
graphics (age, gender), additional risk factors (e.g. smok-
ing history, diabetes), trial year, trial size, trial duration,
trial blinding, and the proportion of subjects that were
blood pressure treatment naïve, had past treatment or
were on current treatment at trial entry. We also
recorded whether add-on treatment was permitted in
either arm if protocol defined blood pressure targets
were not met and the proportion that required that
add-on treatment. No publication included individual
level data for analysis.
Data analysis
The surrogate endpoint independent variables were two,
diastolic blood pressure and systolic blood pressure.
Each was a difference between arms of the differences
over the trial for each arm. For diastolic blood pressure
(DBP) the difference over the trial was defined as the
mean baseline DBP in the treated patients minus the
mean on-trial DBP (i.e., all measures from year 1 to
end-of-trial) in the treated patients, and similarly for the
control patients. The DBP independent variable was
then the mean DBP difference in treated patients minus
the mean DBP difference in control patients. The systo-
lic blood pressure independent variable was defined
similarly. Systolic and diastolic blood pressure differ-
ences were analysed separately. The dependent variable
was the relative risk reduction (RRR) of fatal and non-
fatal stroke, i.e., the stroke rate in the control arm
minus the stroke rate in the test arm, divided by the
stroke rate in the control arm. RRR was selected as the
most intuitively understandable outcome metric for clin-
icians. All trial data are from intention-to-treat analysis.
If a trial report pre-specified a comparison combining
treatment arms, these were used. Otherwise, the com-
parison used from multiple arm trials was the compari-
son with the largest difference in BP changes. We used
the BSES3 for the multidimensional quantitative
evaluation of blood pressure reduction as a surrogate
endpoint for stroke events.
Statistical analysis
The independent variable mean blood pressure differ-
ence is an estimated variable; therefore, its true value is
not known with certainty in regression analysis. When
both the independent variable as well as the dependent
variable are measured with error, then the effect of the
independent variable is biased, usually towards the null
(underestimated) [19,20]. There are several errors-in-
variables regression methods that have been proposed to
adjust for this bias [20]. One method adjusts for the bias
by incorporating knowledge of the reliability, r, (where r
= 1- (noise variance/total variance)) of the independent
variable. Therefore we undertook a weighted (by trial
size) errors-in-variables regression of relative risk reduc-
tion (RRR) of fatal and non-fatal stroke on systolic and
diastolic blood pressure reduction respectively, incorpor-
ating sensitivity analyses with reliabilities of 0.6, 0.7, 0.8
and 0.9, where 1.0 indicates no measurement error. The
weighting was applied to (i) estimates of the linear pre-
diction, (ii) the standard error of the predicted expected
value and (iii) the standard error of the point prediction
for a single observation, commonly referred to as the
standard error of the future or forecast value. We used
data from the literature to inform these reliabilities as
there have been many studies that report within and
between individual, as well as within and between group
variability of systolic and diastolic blood pressure, plus
specific studies of sources of variability including mea-
surement error of blood pressure observations. We used
Tobit regression (assuming no uncertainty in the esti-
mated surrogate) [21] because relative risk reduction is
bounded at 1.0, representing 100% increase. We also
used fractional polynomial regression [22] to confirm
that a linear model was satisfactory. Other regression
assumptions were evaluated using standard methods.
The surrogate threshold effect (STE) is the minimum
by-arm blood pressure reduction difference that predicts
a by-arm stroke reduction benefit. Graphically, this is
where the regression lower 95% prediction line [23] for
an individual trial crosses the horizontal axis represent-
ing no stroke reduction benefit [9]. Other statistics
reported are the R-squared at the trial level (R
2
trial-level)
of the weighted errors-in-variables regression model as
well as the coefficient (slope) of the blood pressure
reduction difference. No publication included individual
l e v e ld a t at h e r e f o r e ,w ew e r eu n a b l et od e t e r m i n et h e
patient-level association between both endpoints
(R
2
individual).
Given that reduction of blood pressure with antihyper-
tensive drugs has a greater effect on stroke prevention
than on reduction of cardiovascular mortality or on all-
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Page 5 of 21cause mortality [24,25], we evaluated the construct
validity of the STE by repeating all the statistical ana-
lyses with cardiovascular deaths and all-cause deaths as
the patient-relevant clinical endpoints. We used Stata 11
for all analyses.
Results
The search of the 38 meta-analyses yielded 197 individual
trials that were greater than 6 months duration and were
of any anti-hypertensive pharmacologic treatment. Hand-
searching of the citations from these trial reports did not
identify any trials missed by the 38 meta-analyses. All
197 trials including all secondary reports and
publications were reviewed and data extracted. Of these
63 were for at least six months of pharmacologic treat-
ment for primary or secondary prevention and were not
excluded based on exclusion criteria (i) to (v). Of these
48 reported pre- and on-trial blood pressure and cerebro-
vascular events. Of these, 39 had at least 5 cerebrovascu-
lar events in each arm. Of these, 18 were negatively
controlled [26-43] (see Figure 2 flow chart); all but one,
HYVET-pilot [39], used placebo and were blinded. Trial,
clinical and pharmacologic characteristics of these 18
trials are described in Table 1. One trial, ANBP1[26],
reported only DBP differences. Trial size, BP reductions,
and stroke event numbers are shown in Table 2.
 
 
 
 
 
 
 
 
134 met exclusion criteria (i) to(v) 
15 excluded because did not report by-arm 
baseline or on-trial blood pressure or by-
arm number of events for fatal and non-
fatal stroke. 
1161 excluded because were not meta-analyses, were 
of insufficient duration, did not address adult patients, 
or were derivative analyses of earlier meta-analyses 
with no new trials. 
38 meta-analyses or systematic reviews reported trials that satisfied our inclusion 
criteria (see supplementary material for references) and were reviewed. These 
identified 197 trials of at least six months of any anti-hypertensive pharmacologic 
treatment for primary or secondary prevention. All 197 trials were reviewed. 
18 trials met all criteria and were included in the statistical model 
9 trials excluded because fewer than five 
cerebrovascular (CVA) events per arm 
1199 meta-analyses Medline search 1950 to May 2009 (exp Hypertension/(181,231) OR exp Blood 
Pressure/(216,603) OR (blood pressure or hyperten* or systolic or diastolic).mp. (538,084); limited to 
humans AND adults AND to meta-analysis OR reviews OR systematic reviews. All abstracts reviewed. 
21 excluded because control arm was 
mandatory active antihypertensive drug(s) 
Figure 2 Flow chart of articles. (also see Table 1 and Additional file1).
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trials, a beta-blocker in 5 trials, a calcium channel block-
ers in 3 trials, an angiotensin converting enzyme (ACE)
inhibitor in 4 trials and an angiotensin II receptor
antagonists in 2 trials. Only one trial, PATS [33], limited
treatment to a single pharmacologic class. Ten trials
included treatment from three or more pharmacologic
classes. Seven of the 18 trials included a variable propor-
tion of patients on diuretics, beta-blockers, calcium
channel blockers or ACE inhibitors, either at study
entry (background therapy) or as add-on during the
trial. Six of these 7 were trials published in the last 10
years. In only 4 trials (ANBP1[26], MRC-mild[28], HEP
[29], MRC-elderly [32]) were all subjects antihyperten-
sive treatment naïve at trial onset. Nine trials were con-
ducted in the primary prevention setting. Mean trial
duration was 3.9 years. Only one trial was less than two
years in duration (HYVET-pilot [39] with a mean
duration of treatment of 1.1 years) and 11 were four or
more years. Mean age of subjects across the 18 trials
was 66 years and 55% were male. Mean blood pressure
at trial entry was 160 mmHg systolic and 90 mmHg
diastolic.
The by-trial scatterplot of stroke relative risk and sys-
tolic blood pressure difference labelled by trial name is
shown in upper graph of Figure 3. The lower graph in
Figure 3 shows the same scatterplot weighted by trial
size and the by-trial weighted least squares regression of
stroke relative risk and systolic blood pressure difference
assuming no uncertainty in the estimated systolic blood
pressure difference. The upper and lower bold solid
lines are the upper and lower 95% prediction limits, the
dashed inner lines are the 95% confidence limits, the
dot-dash centre line is the mean regression line. The
arrow indicates where the lower 95% prediction line
intersects the horizontal axis at approximately 7.4
Table 1 Trial, clinical and pharmacologic characteristics of the 18 trials that met inclusion criteria
Trial Year Trial
Size
Mean
Trial
Duration
(yrs)
Prevention Drug
(first agent/s)
Add
on
Drug
(s)#
Drug
Class*
Mean
SBP*
at
base-
line
Mean
DBP*
at
base-
line
Mean
Age
Male
%
Diabetes
%
Smoker
%
ANBP1 [26] 1980 3427 4 Primary chlorothiazide N 0,1,2 157.4 100.5 50.4 63.0 0.0 25.0
IPPPSH [27] 1985 6357 4 Mixed Oxprenolol Y 1,2 173.0 107.5 52.2 50.2 29.1
MRC-mild
[28]
1985 17354 5 Mixed bendrofluazide or
propranolol
N 1,2 161.5 98.5 50.0 50.0 31.0
HEP [29] 1986 884 8 Primary Atenolol N 0,1,2 196.4 98.9 68.8 30.9 0.0 24.3
SHEP [30] 1991 4736 4.5 Primary Chlorthalidone N 1,2 170.3 76.6 71.6 43.2 10.1 12.7
STOP [31] 1991 1627 2.1 Primary atenolol or
hydrochlorothiazide
+ amiloride or
metoprolol or pindolol
N 1,2 195.0 102.0 75.7 37.0 8.0
MRC-elderly
[32]
1992 4396 5.8 Primary atenolol or amiloride/
hydrochlorothiazide
N 1,2 184.7 90.7 70.3 41.8 0.0 17.5
PATS [33] 1995 5665 2 Secondary Indapamide N 1 153.8 92.8 60.0 72.0
Syst-Eur [34] 1997 4695 2 Primary Nitrendipine N 1,3,4 173.9 85.5 70.3 33.2 7.3
PREVENT
[35]
2000 825 3 Secondary Amlodipine Y 2,3,4 129.4 78.9 56.9 80.1 24.7
PROGRESS
[36]
2001 6105 4 Secondary Perindopril N 1,3 147.0 86.0 64.0 70.0 12.5 20.0
EUROPA [37] 2003 12218 4.2 Secondary Perindopril Y 1,2,3,4 137.0 82.0 60.0 85.4 12.3
SCOPE [38] 2003 4937 3.7 Primary Candesartan Y 1,2,3,4,5 166.3 90.4 76.4 35.5 12.0 8.7
HYVET-pilot
[39]
2003 857 1.1 Primary bendroflumethiazide
or lisinopril
N 1,3,4 181.5 99.6 83.8 36.6 4.2
PEACE [40] 2004 8290 4.8 Secondary Trandolapril Y 1,2,3,4 133.5 78.0 64.0 82.0 17.0 14.5
ACTION [41] 2004 7665 4.9 Secondary Nifedipine Y 1,2,3,4 137.5 79.9 63.4 79.4 14.5 17.7
TRANSCEND
[42]
2008 5926 4.7 Secondary Telmisartan Y 1,2,4,5 141.0 81.9 66.9 57.0 35.7 9.8
HYVET-main
[43]
2008 3845 2.1 Primary Indapamide N 1,4 173.0 90.8 83.6 39.5 6.8 6.5
# Possible anti-hypertensive pharmacologic treatment at entry or add-on during trial to any trial arm. *Drug Class: 0 = older drugs (methyldopa, clonidine etc), 1
= diuretics, 2 = beta-blockers 3 = angiotensin converting enzyme (ACE) inhibitors, 4 = calcium channel blockers (CCBs), 5 = angiotensin receptor blockers (ARBs,
also called angiotensin II receptor antagonists (AIIRA))
Lassere et al. BMC Medical Research Methodology 2012, 12:27
http://www.biomedcentral.com/1471-2288/12/27
Page 7 of 21mmHg. This is the surrogate threshold effect (STE).
This means that a future trial would need a SBP differ-
ence, active versus control, of at least 7.4 mmHg to
ensure a stroke reduction benefit. The slope of the
regression line is positive at 0.02 (p < 0.01) and the R
2
was 0.37.
The results for diastolic blood pressure are in Figure
4. The surrogate threshold effect is 2.6 mmHg. The
slope of the regression line is positive at 0.045 (p <
0.001) and the R
2 is 0.58.
Baseline blood pressure was not a significant coefficient.
Table 3 shows the results for the errors-in-variables
regression with 0.9, 0.8, 0.7 and 0.6 reliability coefficients
for both systolic and diastolic blood pressure respectively.
These results include the slope (coefficient of systolic and
diastolic mean blood pressure reduction), the p-value for
the slope, the R-squared of the linear regression model,
the STE and the STEP. The slope and R-squared of the
linear regression model increase as the reliability coeffi-
cient decreases. This in turn decreases the STE and
increases the STEP. Figure 5 shows the graphs of the scat-
terplot weighted by trial size and the by-trial weighted
least squares regression of stroke relative risk and systolic
blood pressure difference assuming reliability coefficient of
0.9 and 0.7. Figure 6 shows the results for diastolic blood
pressure for these same reliability coefficients.
In contrast to stroke, no STE could predict a cardiovas-
cular mortality benefit. Assuming a reliability coefficient of
1.0 (i.e. no measurement error in the surrogate) for systo-
lic blood pressure, the slope of the mean regression line is
0.009 and is non-significant, the R-square is 0.15, the STE
approaches the x axis at 25 mmHg, but it does not cross
the axis; therefore, there is no STE and no STEP. In dia-
stolic blood pressure the slope is 0.012 and is also non-sig-
nificant, the R-squared is only 0.05 and the STE
approaches no value of diastolic blood pressure reduction
within the model data-points. These results are displayed
in Figure 7. The upper 3 graphs are the results for systolic
blood pressure and the lower 3 graphs for diastolic blood
pressure. The left-side graph shows the scatterplot
weighted by trial size and labelled by the trial name. The
middle and right-side graphs show the weighted least
squares regression of cardiovascular mortality relative risk
assuming reliability coefficient of 1.0 and 0.7.
Similarly, no STE predicts an all-cause mortality bene-
fit. Assuming a reliability coefficient of 1.0 (i.e. no mea-
surement error in the surrogate) for systolic blood
pressure, the slope is 0.005 and is non-significant, the
R-squared is 0.06, the STE approaches infinity. In dia-
stolic blood pressure the slope is 0.005 and is also non-
significant, the R-squared is only 0.02 and there is no
STE. These results are displayed in Figure 8.
Table 2 Trial size, blood pressure difference (mean change in active arm minus mean change in control arm), stroke
events and stroke relative risk reduction
Trial Year No.
Subject
sI n
Active
Arm
No. Of
Subjec
ts In
Contro
l Arm
Systolic
Blood
Pressure
Difference
Diastolic
Blood
Pressure
Difference
Stroke
events in
Active
Arm
Stroke
events in
Control
Arm
Stroke
Relative
Risk
Reduction
ANBP1 [26] 1980 1721 1706 NR 5.7 13 22 0.41
IPPPSH [27] 1985 3185 3172 3.8 0.2 45 46 0.03
MRC-mild [28] 1985 8700 8654 10.3 6.2 60 109 0.45
HEP [29] 1986 419 465 18.0 11.0 23 44 0.42
SHEP [30] 1991 2365 2371 12.4 4.3 106 163 0.35
STOP [31] 1991 812 815 22.5 10.5 29 53 0.45
MRC-elderly [32] 1992 2183 2213 14.3 7.2 101 134 0.24
PATS [33] 1995 2824 2841 5.9 3.0 159 217 0.26
Syst-Eur [34] 1997 2398 2297 9.4 5.5 49 80 0.41
PREVENT [35] 2000 417 408 6.8 3.9 5 5 0.02
PROGRESS [36] 2001 3051 3054 9.0 4.0 317 420 0.24
EUROPA [37] 2003 6110 6108 5.0 2.0 98 102 0.04
SCOPE [38] 2003 2477 2460 3.5 2.9 89 115 0.23
HYVET-pilot [39] 2003 431 426 23.9 11.1 12 18 0.34
PEACE [40] 2004 4158 4132 3.0 1.2 71 92 0.23
ACTION [41] 2004 3825 3840 4.7 3.1 82 108 0.24
TRANSCEND [42] 2008 2954 2972 3.4 2.0 112 136 0.17
HYVET-main [43] 2008 1933 1912 12.0 6.0 51 69 0.27
NR = Not Reported
Lassere et al. BMC Medical Research Methodology 2012, 12:27
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Figure 3 Stroke relative risk reduction and systolic BP difference - no measurement error. Upper graph: Scatterplot of stroke relative risk
reduction and systolic blood pressure difference reduction showing the 17 trials labelled by trial name. Lower graph: scatterplot weighted by
trial size and by trial weighted least squares regression of stroke relative risk and systolic blood pressure difference reduction assuming no
measurement error (reliability coefficient = 1.0). The upper and lower bold solid lines are the upper and lower 95% prediction limits, the dashed
inner lines are the 95% confidence limits, the dot-dash centre line is the mean regression line. The arrow indicates where the lower 95%
prediction line intersects with the x axis. This is the Surrogate Threshold Effect (STE) for stroke reduction and is the systolic blood pressure
difference needed to impute a stroke reduction benefit in a new trial.
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Figure 4 Stroke relative risk reduction and diastolic BP difference - no measurement error. Upper graph: Scatterplot of stroke relative
risk reduction and diastolic blood pressure difference reduction showing the 18 trials labelled by trial name. Lower graph: scatterplot weighted
by trial size and by trial weighted least squares regression of stroke relative risk and systolic blood pressure difference reduction assuming no
measurement error (reliability coefficient = 1.0). The upper and lower bold solid lines are the upper and lower 95% prediction limits, the dashed
inner lines are the 95% confidence limits, the dot-dash centre line is the mean regression line. The arrow indicates where the lower 95%
prediction line intersects with the x axis. This is the Surrogate Threshold Effect (STE) for stroke reduction and is the diastolic blood pressure
difference needed to impute a stroke reduction benefit in a new trial.
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Page 10 of 21The performance of blood pressure as a surrogate
endpoint for stroke events according to the BSES3 is
reported in Table 4. As we had no patient-level data, we
could not derive the R
2
individual specific to our dataset,
therefore we assumed that the R
2
individual was as least as
large as the R
2
trial. Under assumptions of minimal
uncertainty (reliability coefficient 0.9) systolic blood
pressure reduction is a B + surrogate endpoint for
stroke prevention as there is good statistical evidence
from multiple (n = 17) randomised controlled trials, of
irreversible morbidity (stroke), across different drug
class mechanisms (at least 5) and clinical risk popula-
tions (gender, age, ethnicity and primary/secondary pre-
vention). Under assumptions of uncertainty (reliability
coefficient 0.9) diastolic blood pressure is an A grade
surrogate endpoint for stroke prevention, because it
scored the highest rank on all domains including the
statistical domain (excellent statistical evidence). How-
ever, under the assumption of no uncertainty, (reliability
coefficient 1.0), both systolic and diastolic blood pres-
sure performed less well because they dropped rank on
the statistical domain. The BSES3 requires a valid surro-
gate endpoint to have a combined score of at least 9
(one domain of rank 3 and the remainder at least of
rank 2) and a minimum threshold rank of at least 2
across all domains (see Figure 1). This design prevents a
high score on any one or more domain compensating
for a low score on one or more domain; because good
evidence of surrogacy across all domains is needed to be
a valid surrogate endpoint. If the threshold criterion is
not met, the grade drops by one alphabetic grade.
Systolic blood pressure fell from rank 2 to rank 1 in the
statistical domain. As a result, systolic blood pressure no
longer met the criteria of requiring a minimum rank of
2 across all domains. Although the combined score was
10, the grade dropped from B to C. Diastolic blood
pressure fell from rank 3 to rank 2 on the statistical
domain. Its combined score was 11, but because it met
the minimum rank of 2 across all domains, it held its
grade of B +.
Discussion
Using trial-level data from published negatively con-
trolled randomised trials of anti-hypertensive drugs we
formally evaluated the evidence that supports systolic
and diastolic blood pressure reduction as a surrogate
endpoint for stroke reduction. We also determined the
STE for systolic and diastolic blood pressure, i.e., the
minimum systolic and diastolic blood pressure differ-
ence needed in a new trial to predict a stroke benefit.
Using errors-in-variables regression weighted by trial
size, and assuming minimal uncertainty (reliability coef-
ficient 0.9) estimating trial-level systolic and diastolic
blood pressure reduction, the STE for systolic blood
pressure is 7.1 mmHg and the STE for diastolic blood
pressure is 2.4 mmHg. Furthermore, assuming having
patient-level data would not influence the results on the
BSES3, systolic blood pressure is a Grade B + surrogate
endpoint for stroke protection and diastolic blood pres-
sure is a Grade A surrogate endpoint for stroke protec-
tion. A discussion of the assumptions that underpin
these results, supporting evidence, and caveats are fun-
damental to the debate on surrogate endpoint evaluation
specific to blood pressure as well as to other biomarkers
and patient-reported instruments.
Context of surrogacy and impact of secular change in
study design, trial populations and treatment modalities
These STEs for systolic and diastolic blood pressure
assume that the new trial measuring only the surrogate
endpoint is otherwise similar to past trials used in the
predictive model regarding intervention, population,
trial design and pharmacologic therapy. These STEs
were derived from negatively controlled antihypertensive
randomised controlled trials of varying design, clinical
populations and pharmacologic classes. Therefore, these
STEs may not be applicable to trials that require sub-
jects in all arms to be randomised to an anti-hyperten-
sive drug, or to trials of homogeneous populations, for
example, trials of only heart or renal failure patients. As
our data-set of trials spans four decades, secular changes
in standard of care of hypertension is to be expected
and is reflected in changes in trial design and in relation
to inclusion and exclusion crit e r i ao fr i s kp o p u l a t i o n s .
At one extreme, severe hypertension rapidly became
Table 3 Weighted ordinary least squares errors-in-
variables regression of stroke relative risk reduction and
systolic and diastolic blood pressure difference
respectively, assuming 0.9, 0.8, 0.7 and 0.6 reliability
coefficients for estimated blood pressure difference
Reliability
coefficient
Regression
Slope
Regression
Slope
p-value
R
2 STE* STEP**
Systolic Blood Pressure
1.0 0.0196 0.010 0.37 7.4 64%
0.9 0.0217 0.008 0.41 7.1 66%
0.8 0.0245 0.006 0.46 6.7 68%
0.7 0.0280 0.004 0.52 6.3 70%
0.6 0.0327 0.002 0.61 5.9 72%
Diastolic Blood Pressure
1.0 0.0453 0.000 0.58 2.6 76%
0.9 0.0503 0.000 0.64 2.4 78%
0.8 0.0566 0.000 0.72 2.2 80%
0.7 0.0647 0.000 0.83 1.9 83%
0.6 0.0755 0.000 0.96 1.2 88%
* Surrogate Threshold Effect ** Surrogate Threshold Effect Proportion
Lassere et al. BMC Medical Research Methodology 2012, 12:27
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Figure 5 Stroke relative risk reduction and systolic BP difference - errors-in-variables. Upper graph: scatterplot weighted by trial size and
by trial errors-in-variables (eiv) weighted least squares regression of stroke relative risk and systolic blood pressure difference reduction assuming
measurement error (reliability coefficient = 0.9). Lower graph: scatterplot weighted by trial size and by trial eiv weighted least squares regression
of stroke relative risk and systolic blood pressure difference reduction assuming measurement error (reliability coefficient = 0.7). The upper and
lower bold solid lines are the upper and lower 95% prediction limits, the dashed inner lines are the 95% confidence limits, the dot-dash centre
line is the mean regression line. The arrow indicates where the lower 95% prediction line intersects with the x axis. This is the Surrogate
Threshold Effect (STE) for stroke reduction and is the systolic blood pressure difference needed to impute a stroke reduction benefit in a new
trial given eiv regression.
Lassere et al. BMC Medical Research Methodology 2012, 12:27
http://www.biomedcentral.com/1471-2288/12/27
Page 12 of 21		
















































 
!
"



#

  
         
 

 
 

$"% &!$''#"
 !"## $"%&$''#"()

		
















































 
!
"



#

  
         
 

 
 

$"% &!$''#"
 !"## $"%&$''#"()
Figure 6 Stroke relative risk reduction and diastolic BP difference - errors-in-variables. Upper graph: scatterplot weighted by trial size
and by trial errors-in-variables (eiv) weighted least squares regression of stroke relative risk and diastolic blood pressure difference reduction
assuming measurement error (reliability coefficient = 0.9). Lower graph: scatterplot weighted by trial size and by trial eiv weighted least squares
regression of stroke relative risk and diastolic blood pressure difference reduction assuming measurement error (reliability coefficient = 0.7). The
upper and lower bold solid lines are the upper and lower 95% prediction limits, the dashed inner lines are the 95% confidence limits, the dot-
dash centre line is the mean regression line. The arrow indicates where the lower 95% prediction line intersects with the x axis. This is the
Surrogate Threshold Effect (STE) for stroke reduction and is the diastolic blood pressure difference needed to impute a stroke reduction benefit
in a new trial given eiv regression.
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Page 13 of 21incompatible with trials with no treatment controls.
Another secular change is the large number of different
pharmacologic classes of agents used singly and in com-
bination. As the evidence for the benefits of blood pres-
sure reduction accrued, equipoise for negatively
controlled trials diminished, and as more pharmacologic
classes of anti-hypertensive agents appeared, polyphar-
macy became the rule. Few patients were treatment-
naïve, and trials increasingly used designs with provi-
sions for add-on to established “background” regimens.
Trial entry criteria changed as did the cut-off for man-
datory discontinuation in the event of the on-trial devel-
opment of severe, uncontrolled hypertension. Older
patients and those with lower entry BP and improved
risk profiles generally were increasingly enrolled in more
recent trials. In seven trials, a proportion of enrolled
patients (sometimes up to half) were already on antihy-
pertensive drugs either for hypertension or other indica-
tions. We did not exclude these trials because they met
our inclusion criteria. Also, to capture drug effects that
may occur with BP lowering from a baseline high-nor-
mal range, we did not require elevated BP at baseline.
Cross-over also occurred in some trials, although gener-
ally it was less than 15% and occurred from active to
control arm as well as in the other direction. Only four
trials recruited treatment-naïve patients exclusively,
where one might expect greater BP and outcome
responses compared to trials with treatment-experienced
patients. Fourteen trials had varying proportions of
treatment-naïve versus treatment-experienced patients
which also might dilute or delay the effect on stroke
reduction. These changes are likely to attenuate the
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Figure 7 Cardiovascular mortality relative risk reduction and BP difference.Upper graphs: Left: Scatterplot of cardiovascular mortality
(CVM) relative risk reduction (RRR) and systolic blood pressure difference reduction showing the trials labelled by trial name. Middle: scatterplot
weighted by trial size and by trial weighted least squares regression of cardiovascular mortality relative risk reduction and systolic blood pressure
difference reduction assuming no measurement error (reliability coefficient = 1.0). Right: scatterplot weighted by trial size and by trial weighted
least squares regression of cardiovascular mortality relative risk reduction and systolic blood pressure difference reduction assuming
measurement error (reliability coefficient = 0.7). Lower graphs: show the results for diastolic blood pressure. The upper and lower bold solid
lines are the upper and lower 95% prediction limits, the dashed inner lines are the 95% confidence limits, the dot-dash centre line is the mean
regression line. There is no Surrogate Threshold Effect (STE) to impute a CV mortality benefit in a new trial.
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Figure 8 All-cause mortality relative risk reduction and BP difference. Upper graphs: Left: Scatterplot of all-cause mortality (ACM) relative
risk reduction (RRR) and systolic blood pressure difference reduction showing the trials labelled by trial name. Middle: scatterplot weighted by
trial size and by trial weighted least squares regression of all-cause mortality relative risk reduction and systolic blood pressure difference
reduction assuming no measurement error (reliability coefficient = 1.0). Right: scatterplot weighted by trial size and by trial weighted least
squares regression of all-cause mortality relative risk reduction and systolic blood pressure difference reduction assuming measurement error
(reliability coefficient = 0.7). Lower graphs: show the results for diastolic blood pressure. The upper and lower bold solid lines are the upper and
lower 95% prediction limits, the dashed inner lines are the 95% confidence limits, the dot-dash centre line is the mean regression line. There is
no Surrogate Threshold Effect (STE) to impute an all-cause mortality benefit in a new trial.
Table 4 The surrogacy status of blood pressure reduction for stroke prevention on the BSES3 assuming a reliability
coefficient of r = 1.0 (no uncertainty) and assuming a reliability coefficient of r=0.9 (minimal uncertainty)
Study
Design
Target
Outcome
Statistical
Relationship
Note1
Generalisability Combined Grade
Systolic
r = 1.0
33 1 31 0 C
See Note
2
Systolic
r = 0.9
33 2 31 1 B +
Diastolic
r = 1.0
33 2 31 1 B +
Diastolic
r = 0.9
33 3 31 2 A
Note 1: We did not have individual level data from any randomised controlled trial needed to evaluate individual-level associations therefore we assumed that
the Rindividual
2 was as least as large as the R
2
trial
Note 2: Although the combined score is 10, the statistical relationship was less than rank 2, therefore the grade drops from B to C
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the compilation of new data supporting surrogacy, and
increase the size of the STE. It is likely that the STEs
estimated from active-control randomised trials would
be larger because subjects in all arms are randomised to
hypertensive drugs. Furthermore, trials clinically of
homogeneous populations, such as heart or renal failure
populations may also have different STEs. These
hypotheses, if substantiated, imply that the initial evalua-
tion of all existing and new biomarkers should be in
negatively controlled heterogeneous randomised trials;
otherwise, the surrogacy potential of these biomarkers
may be underestimated.
Regression modelling with measurement error in the
independent variable: Application to blood pressure
Ordinary linear regression has several assumptions, one
b e i n gt h a ta l lv a r i a t i o ni si nt h ed e p e n d e n tv a r i a b l ea n d
that as long as these measurement errors are uncorre-
lated and unbiased the results are not influenced. How-
ever, the independent variable must be measured
without error. In the presence of random measurement
error in the independent variable coefficients are biased
towards the null. In our analysis both stroke relative risk
reduction and mean blood pressure reduction are trial-
level estimations. Therefore, a priori, they are measured
with error. Unfortunately, trials did not report the
within arm standard deviation of blood pressure reduc-
tion. Individual blood pressure readings are highly vari-
able, because of position, rest, etc, and measurement
errors due to the instrument and observer [44,45]. Sys-
tematic bias, such as white coat hypertension [46], is
generally less problematic in the setting of a randomised
controlled trial. Hebel [47] evaluated within-person
variability of diastolic BP. Within occasion variability
was 3.1 mmHg for patients on medication and 2.4
mmHg for normotensive controls. Reliability coefficients
of 0.6 to 0.9 have been reported [48-52]. Skirton [53]
recently undertook a systematic review of variability and
reliability of manual and automated blood pressure
readings, but none of the results were reported as relia-
bility coefficients. The importance of blood pressure
variability as a predictor of vascular events is a new
direction of research [54]. The underestimation of risk
association due to regression dilution in long-term pro-
spective studies has also been well described in studies
of hypertension [55,56]. Therefore, our linear regression
model is influenced by several sources of variation all of
which, assuming no systematic variation, underestimate
the slope of the relationship between stroke relative risk
reduction and blood pressure reduction. Therefore, our
results are conservative, and we illustrate the effect of
adjusting for the error in the independent variable by
sensitivity analysis using several reliability coefficients.
Using errors-in-variables regression systolic STEs vary
from 7.4 mmHg (assuming no uncertainty around the
estimated effects on the independent variable) to 5.9
(assuming a reliability coefficient as low as 0.6). The dia-
stolic STEs vary from 2.6 mmHg (assuming no uncer-
tainty around the estimated effects on the independent
variable) to as little as1.2 (again assuming a reliability
coefficient as low as 0.6). Interestingly, the difference in
STEs across these different reliability coefficients was
only 1.5 and 1.4 mmHg for systolic and diastolic blood
pressure respectively, a indicator of the robustness of
STE and the STEP as a method of evaluating surrogacy.
There was a much greater impact of different reliability
coefficients on the R-squared trial-level association.
These almost doubled for both systolic and diastolic
blood pressure (R-squared 0.37 to 0.61 and 0.58 to 0.96)
with increasing correction for measurement error. We
used the reliability coefficient errors-in-variables regres-
sion (as provided by Stata statistical software), however,
several other methods have been proposed [19,20] and
comparing the results of different methods would be
worthy of further research.
Statistical measures of surrogacy
Surrogacy is a complex construct and requires several
qualitatively different statistical (and substantive) metrics
for its evaluation. We were limited to the STE, the STEP
and trial-level linear regression to statistically evaluate
blood pressure’s surrogacy status. We did not have
access to any patient-level data, therefore, were unable
to evaluate surrogacy status on an individual-level.
Other approaches have been proposed, including a
mixed models analysis [7] that combine time, surrogate,
clinical endpoint, treatment, trial and individual subject
variables into a single analysis for estimation of a mixed
model trial-level association, a mixed model individual-
level association and a mixed model STE. Other new
methods are those based on principal stratification [57].
The STEP is useful because it identifies the relative
position of the STE within the model of data used to
determine the STE by converting a unit-specific STE, e.
g. mmHg of blood pressure, to a proportion. It is similar
to the coefficient of determinations in that it can take a
value from 0.0 to 1.0 (or 0% to 100%). The STEP serves
to compare STEs across different contexts. We have
already shown that the STE is more robust to measure-
ment error than the R-squared trial-level association;
therefore, the STEP may also be a more robust method
of comparing different surrogate endpoints.
Our trial-level association for systolic blood pressure
may be considered low (R-squared 0.37 assuming no
uncertainty). The results for diastolic blood pressure
were somewhat better (R-squared 0.58 assuming no
uncertainty). Trial-level associations of reported
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are those that evaluate progression-free survival, disease-
free survival and event-free survival as a surrogate end-
point for overall survival, where survival is included in
the surrogate [58-60]. Analyses of time to progression
or response rate surrogate endpoints, measures that do
not include a survival in the surrogate, report more
modest trial-level associations. In metastatic colon dis-
ease the trial-level association of time to progression
w a s0 . 3 3[ 1 0 ] .B i o m a r k e r si nn o n - o n c o l o g i c a lc h r o n i c
disease also have trial-level associations that are modest.
In negatively-controlled randomised trials of statins the
trial-level association of LDL-cholesterol reduction and
cardiovascular mortality reduction assuming no uncer-
tainty was 0.41 [11].
Previously published models and meta-analyses of stroke
and other vascular outcomes
Others have found similar relationships using different
regression methods relating BP differences and expected
outcome differences, but none calculated prediction
bands to estimate an STE. Staessen et al [16] was the
first to publish a blood pressure trial level regression.
Using data from hypertension outcome trials of at least
2-years duration and at least 100 patients, they reported
trial-level regression models of the odds ratio of cardio-
vascular mortality and all cardiovascular events versus
systolic blood pressure difference. Graphically, a systolic
BP difference of 5 mmHg corresponded to a cardiovas-
cular mortality reduction of about 10%. In our data-set
of trials, designed to identify stroke outcomes, a systolic
blood pressure reduction of 10 mmg was associated
with a 9% reduction of cardiovascular mortality, but the
result was not statistically significant. Law et al [18]
published a meta-analysis of stroke in 45 trials (includ-
ing trials in conditions other than essential hyperten-
sion) demonstrating a 5 mmHg diastolic blood pressure
or 10 mmHg SBP reduction corresponded to a 41%
reduction in stroke. However, among the 45 trials were
studies in patients with coronary heart disease that
reported no BP data at all, and for these trials BP
changes were imputed from results from an earlier
study of short term BP studies [61]. We found, in our
trial-dataset, a 5 mmHg DBP reduction or 10 mmHg
SBP reduction corresponded to a 22.5% and 20% reduc-
tion in stroke respectively, assuming a no measurement
error model. Boissel et al [62] in the INDANA data set
that included individual patient data reported a Cox
proportional hazard model of stroke in the five trials
(28,997 patients, 808 events). They found a hazard ratio
for stroke of 0.79, a risk reduction of 21%. In this study
about one-half of the benefit was accounted for when
adding an adjustment made for on-treatment BP and BP
measurement error, a result interpreted by the authors
as suggesting that only half of the stroke benefit is
“explained by” the effect of treatment on blood pressure.
We found that baseline blood pressure was not a signifi-
cant predictor of stroke events, a result confirmed by
others [63].
Others have also found that the relationship for stroke
reduction is stronger than that for cardiovascular mor-
tality or all-cause mortality reduction [24]. We therefore
would expect the STE for mortality reduction to be lar-
ger than the STE for stroke reduction. All trials in our
data reported all-cause fatal events and all but one
(PREVENT [35]) reported cardiovascular fatal events.
Trial-level associations for both systolic and diastolic
blood pressure reduction and cardiovascular mortality
and all-cause mortality relative risk reduction were
extremely poor, less than 0.15 for systolic and 0.05 for
diastolic blood pressure, assuming no measurement
uncertainty. We were surprised to find that the relation-
ship between blood pressure reduction and mortality
reduction in our stroke dataset was too poor for an STE
to be estimated. In our stroke data-set, there was no
blood pressure reduction that predicted a mortality ben-
efit. Although these findings provide additional support
for the validity of the stroke-specific STEs, we cannot
conclude that there is no STE for mortality reduction.
Our dataset a required at least 5 stroke outcomes per
treatment arm. To determine the STEs for cardiovascu-
lar mortality and all-cause mortality, a search strategy
specific to this research question is needed. A less con-
servative statistical analysis using mixed models and
individual-level data may also prove necessary before we
conclude that blood pressure is not a valid surrogate
endpoint for mortality endpoints.
Potential limitations and further qualifications of the STE
and other conclusions
Are there any caveats that may bias the STE and our
conclusions towards non-conservative results? We pro-
pose that the STE, STEP and trial-level associations we
have reported are conservative. As we only had access
to trial level data we could not undertake a full hier-
archical mixed model regression. Our model could also
be vulnerable to ecological bias. Our preliminary unpub-
lished simulation work in SAS on comparing ordinary
least squares (OLS) regression with a joint hierarchical
linear mixed model has indicated that OLS regression
STE is almost always larger therefore conservative com-
pared to the STE obtained from the linear mixed model.
In fact, the exceptional simulation scenarios seem to be
clinically highly implausible ones; for example, models
with very few (5) trials, very small (50 patients) trials, or
very small between-trial outcome variance compared to
the patient-level outcome variance. Furthermore, these
scenarios presented computational problems when
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computationally straightforward. In fact, because of its
ability to incorporate both trial and patient-level var-
iances, the mixed model may be expected to produce
narrower prediction bands.
Our simulation work also suggests that the OLS STE
is not influenced by individual-level correlation between
surrogate and true endpoints. Therefore, the STE may
be less subject to ecological bias. Individual-level corre-
lation is usually first explored in observation cohort stu-
dies, as was the case in blood pressure, and is often the
basis for subsequent evaluation in randomised con-
trolled trials.
Other potential methodological weaknesses that may
bias the STE towards a non-conservative value deserve
mention. Even though some individual patient analyses
suggest the hazard ratio for stroke varies over time [64],
we assume the hazard is constant; individual patient
data are needed to study this question. Incorporating
patient-level variability could increase the STE, but, to
date, we have not found that patient-level variability is
as great an influence on the STE as number of trials
and between-trial outcome variance in our simulations.
Nevertheless, patient-level data would facilitate greater
exploration of differences in trial populations over time
and may generate more precise context-specific STEs.
Although expecting that all patient level data on all
trials to be available through publication is unrealistic,
analysis informed by a incorporating a random subset of
patient level data may prove useful and deserves further
investigation. Another issue we considered is whether it
is necessary to calculate a confidence interval around
the STE. This was discussed at a recent international
workshop on biomarkers as surrogate endpoints (Sydney
Bio-Surrogates Workshop, February 2011, unpublished),
and most workshop participants did not think it appro-
priate to calculate a confidence interval around a predic-
tion interval.
Concepts to define surrogacy evaluation and qualification
past, present and future: Lessons learned from the
evaluation of blood pressure
It is important that the concepts that define surrogate
validity are developed in a properly conceived context.
Formal statistical, rather than anecdotal, evaluation of
rigorously defined populations and other context-deter-
mined heterogeneity is needed to systematically explore
and compare surrogacy status of biomarkers and
patient-reported instruments. Our results support that
diastolic blood pressure reduction is a very good surro-
gate for stroke prevention. Systolic blood pressure per-
forms less well. Our analysis of mortality endpoints
indicates that the surrogacy of blood pressure is more
context specific than generally appreciated. The context
could be drug-class specific, clinical endpoint specific
and clinical population specific (i.e., by age, gender, eth-
nicity and comorbidity). How much is the effect on car-
diovascular mortality mediated by blood pressure
reduction, and how much by other drug class effects?
Once the clinical endpoint is broadened to all-cause
mortality, the effect of blood pressure is further diluted
by other drug class effects, including drug class toxicity.
Recently it has been shown that different drug classes
mediate a heterogeneous effect on stroke through vari-
able effects of blood pressure visit-to-visit variability
[65] and visit-to-visit variability is an independent risk
factor for vascular events. It is likely that risk predic-
tions that include a composite surrogate endpoint of
mean blood pressure reduction and reduced blood pres-
sure variability and instability might estimate different
STEs and provide stronger evidence of surrogacy for
blood pressure [66] across a variety of clinical endpoints.
Using the BSES the surrogacy status of different bio-
markers and patient-reported instruments can be com-
pared within these specified contexts. The STE, a trial-
level metric, is a useful measure because it provides
information on the surrogate endpoint in the units of
t h es u r r o g a t ea n dt h e r e f o r ec o u l db eu s e dt oi n f o r m
drug registration and drug reimbursement decisions that
are based on surrogate endpoints. Moreover, the STE is
needed to determine the STEP, which we have shown is
a robust relative metric of surrogacy. We should empha-
sise that we have not analysed data nor do we report a
metric that provide decisions regarding individual
patients, for example, how much to decrease an indivi-
dual patient DBP or what is the optimal final DBP target
to use. For those claims to be data-driven would require,
for example, an RCT to demonstrate that lowering DBP
to, say, 80 mmHg is superior (fewer strokes) than lower-
i n gt h eD B Pt o8 5m m H g .U n d e r t a k i n gs u c h‘target’
trials is feasible but difficult as evidenced by the experi-
ence of the Hypertension Optimal Treatment (HOT)
Study [67,68]. The epidemiology of BP seems to indicate
that even very small BP differences result in difference
in vascular event rates, so, in theory, trials could be
designed to demonstrate a benefit from even very small
BP differences. Policy recommendations would then
need to be made on a numbers-needed-to-treat basis
and, of course, integrated into the other risk factors for
any given patient [69]. These issues are quite distinct
from the strength of evidence of a surrogate, the aim of
the STE and BSES.
Formal evaluation of surrogacy status using a standar-
dised framework, such as the BSES3, can be used to
begin discussions on a surrogate biomarkers qualifica-
tion process [2]. However, surrogacy applications in the
real world of patient-care or policy decisions take into
account other factors that are not included in the
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health, drug safety, disease rarity or diseases that are
serious or life-threatening and where there are no alter-
native therapies, do not directly impact the internal
validity of surrogacy but nevertheless are important con-
siderations for regulators and payors [12]. Nonetheless,
the BSES3 provides clinicians and others a simple hier-
archical framework that can now be used for critically
appraising studies of biomarkers and surrogate
endpoints.
Conclusions
In this report we provide the first surrogate threshold
effect (STE) values for systolic and diastolic blood pres-
sure. The STEs appear to have face and content validity
as evidenced by the inclusivity of trial populations, sub-
ject populations and pharmacologic intervention popula-
tions in their calculation. The STE and STEP metrics
offer another method of evaluating the evidence sup-
porting surrogate endpoints. We have demonstrated
how surrogacy evaluations are strengthened if formally
evaluated within specific-context evaluation frameworks
using the Biomarker- Surrogate Evaluation Schema
(BSES3), and we note the implications of our evaluation
of blood pressure on other biomarkers and patient-
reported instruments in relation to surrogacy metrics
and trial design.
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